Testing Enrotinib plus Paclitaxel antibody for EGFR-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs (Enrotinib and a paclitaxel antibody) for people with advanced lung cancer that has a specific EGFR mutation and has stopped responding to previous EGFR-targeted therapies. It aims to see if this combination can shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have advanced or metastatic non-small cell lung cancer (NSCLC) that cannot be surgically removed or treated with radiation alone.
- Your cancer has an EGFR mutation that used to respond to targeted therapy but no longer does.
- You have not had chemotherapy or radiation for this stage of cancer, or you finished adjuvant chemo more than 6 months ago.
- Your blood counts, liver, and kidney function are within a healthy range.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests two targeted medicines together (aumolertinib plus anlotinib) as first treatment for advanced lung cancer with specific gene changes (EGFR 19del or L858R plus TP53). It aims to see whether the combination is effective and safe when starting treatment.
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
This trial tests a combination of radiation therapy and a targeted drug (Anlotinib) for people with a type of advanced lung cancer that cannot be treated with standard chemoradiation. It may help if your cancer has not spread to other parts of the body and you have not had certain prior treatments.
This trial tests a combination of two targeted drugs (anlotinib and aumolertinib) as the first treatment for advanced lung cancer with a specific EGFR mutation (L858R). The goal is to see if the combination works better than standard care.
This trial tests if anlotinib (a targeted therapy) can help prevent lung cancer from returning after surgery for patients whose tumors did not completely disappear after chemotherapy plus immunotherapy before surgery.
This trial tests a combination of two drugs (tislelizumab and anlotinib) for people with advanced lung cancer whose first immunotherapy treatment stopped working. The goal is to see if this new combination can help when the first treatment stopped being effective.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.